Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28663338 | 0.73 | MEN1 (0.44) | OPRM1OPRK1MEN1NPC1RAB9A | |
| SCHEMBL1260071 | 0.72 | OPRM1 (0.37) | OPRM1OPRL1OPRK1HTR2ACACNA1F | |
| SCHEMBL28487408 | 0.72 | OPRM1 (0.33) | OPRM1OPRL1OPRK1HTR2ACACNA1F | |
| SCHEMBL5028816 | 0.69 | GAA (0.39) | OPRM1OPRL1RAB9AALDH1A1MAPT | |
| SCHEMBL28070658 | 0.68 | OPRM1 (0.34) | OPRM1OPRL1OPRK1HDAC1HDAC2 | |
| SCHEMBL1148182 | 0.68 | MMP2 (0.41) | OPRM1OPRL1OPRK1CHRNB2SLC6A2 | |
| SCHEMBL8205885 | 0.68 | CHRNB2 (0.37) | OPRM1OPRL1OPRK1CHRNB2SLC6A2 | |
| SCHEMBL7607324 | 0.68 | ALOX5 (0.39) | OPRM1OPRL1OPRK1CHRNB2SLC6A2 | |
| SCHEMBL10339222 | 0.67 | HDAC1 (0.38) | OPRM1OPRL1OPRK1CHRNB2SLC6A2 | |
| SCHEMBL27593624 | 0.66 | TDP1 (0.38) | KMT2ACYP1A2MAPTBLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027064-A1 | METHODS OF MAKING AND USING NANOPARTICLES FOR TREATMENT OF BACTERIAL BIOFILM | UNIV BROWN (US) | 2026-01-29 | — | — | US | claimed |
| WO-2024226999-A1 | METHODS OF MAKING AND USING NANOPARTICLES FOR TREATMENT OF MICROBIAL BIOFILMS | BROWN UNIVERSITY (US) | 2024-10-31 | — | — | WO | claimed |
| US-20260027064-A1 | METHODS OF MAKING AND USING NANOPARTICLES FOR TREATMENT OF BACTERIAL BIOFILM | UNIV BROWN (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2024226999-A1 | METHODS OF MAKING AND USING NANOPARTICLES FOR TREATMENT OF MICROBIAL BIOFILMS | BROWN UNIVERSITY (US) | 2024-10-31 | — | — | WO | disclosed |
| CN-108779124-B | Gold porphyrin-PEG conjugates and methods of use | 香港大学 | 2022-03-01 | — | — | CN | disclosed |
| US-11135310-B2 | Gold porphyrin-PEG conjugates and methods of use | THE UNIVERSITY OF HONG KONG (HK) | 2021-10-05 | — | — | US | disclosed |
| EP-3386986-B1 | GOLD PORPHYRIN-PEG CONJUGATES AND METHODS OF USE | UNIV HONG KONG (CN) | 2021-07-21 | — | — | EP | disclosed |
| CN-108779124-A | Gold porphyrin-PEG conjugates and methods of use | 香港大学 | 2018-11-09 | — | — | CN | disclosed |
| EP-3386986-A1 | GOLD PORPHYRIN-PEG CONJUGATES AND METHODS OF USE | The University of Hong Kong (CN) | 2018-10-17 | — | — | EP | disclosed |
| US-10059950-B2 | Compositions comprising an internalizing nucleic acid molecule, and their methods of use | UPSTREAM TECHNOLOGIES, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-20170326252-A1 | Nanoparticles for Delivery of Agents to Glioblastoma Tumors | Nanoforma Inc. (US) | 2017-11-16 | — | — | US | disclosed |
| EP-2839002-B1 | COMPOSITIONS COMPRISING AN INTERNALIZING NUCLEIC ACID MOLECULE, AND THEIR METHODS OF USE | UPSTREAM THERAPEUTICS INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20170240895-A1 | Compositions comprising an internalizing nucleic acid molecule, and their methods of use | B3 BIO INC (US) | 2017-08-24 | — | — | US | disclosed |
| WO-2017097226-A1 | GOLD PORPHYRIN-PEG CONJUGATES AND METHODS OF USE | THE UNIVERSITY OF HONG KONG (CN) | 2017-06-15 | — | — | WO | disclosed |
| US-20170157261-A1 | GOLD PORPHYRIN-PEG CONJUGATES AND METHODS OF USE | THE UNIVERSITY OF HONG KONG (HK) | 2017-06-08 | — | — | US | disclosed |
| EP-2839002-A2 | COMPOSITIONS COMPRISING AN INTERNALIZING NUCLEIC ACID MOLECULE, AND THEIR METHODS OF USE | E3 Group (US) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013158717-A2 | COMPOSITIONS COMPRISING AN INTERNALIZING NUCLEIC ACID MOLECULE, AND THEIR METHODS OF USE | B3 BIO, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027064-A1 | METHODS OF MAKING AND USING NANOPARTICLES FOR TREATMENT OF BACTERIAL BIOFILM | MMP13, MMP9, PGLS | OPRM1 3465/4885OPRL1 3673/4885OPRK1 3342/4885 |
| US-11135310-B2 | Gold porphyrin-PEG conjugates and methods of use | HCCS, PPOX, LIG3 | OPRM1 2159/4885OPRL1 2938/4885OPRK1 3165/4885 |
| US-20170157261-A1 | GOLD PORPHYRIN-PEG CONJUGATES AND METHODS OF USE | HCCS, PPOX, LIG3 | OPRM1 2159/4885OPRL1 2938/4885OPRK1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.